Neurofibromatosis Type I (NF1) and Noonan syndrome (NS), two related disorders with mental health phenotypes, are associated with cognitive deficits in nearly 1 in 2000 people worldwide. Compelling molecular and cognitive parallels between NF1 and NS suggest that their learning problems are caused by a common mechanism. Previous studies in our lab suggested the following mechanistic hypothesis for their cognitive deficits, that we propose to test here: 1) The NS and NF1 gene products regulate the activation of Ras/MAPK/ synapsin I signaling in hippocampal inhibitory terminals;2) This signaling pathway modulates GABA release;3) During learning NS and NF1 mutations result in the over activation of this signaling pathway, abnormally high increases in inhibition, disruptions in the activation of principal neurons, and deficits in the induction of long-term potentiation (LTP).
Our specific aims are: 1. To test the hypotheses that learning triggers SHP-2/neurofibromin/Ras/MAPK-dependent increases in GABA-release, and that the NF1 and NS mouse mutations inappropriately increase these inhibition enhancements and therefore disrupt learning.
This aim will focus on how learning changes inhibition. 2. To test the hypothesis that increased inhibition in Nf1 mice (and potentially NS mutants) prevents the activation of principal neurons in the hippocampus during learning, and consequently causes deficits in hippocampal-dependent learning. We propose to use transgenic fluorophores that track neuronal activity, as well as a novel two-photon imaging technique Micro Optic Probes (MOPs), to track longitudinally the activation patterns of hippocampal CA1 neurons during training in a spatial learning task. 3. To test the hypothesis that SHP-2 activating mutations in mouse hippocampal inhibitory neurons lead to Ras/MAPK/synapsin I-dependent increases in GABA release in the CA1 region, CA1 LTP deficits and hippocampal-dependent learning impairments. To test this hypothesis, we will use mouse mutants we already have and two inducible mutants that will restrict a SHP-2D61G NS mutation to either adult excitatory or inhibitory neurons. We will also use pharmacological inhibitors that target the mechanisms tested, including a FDA-approved drug. We will determine whether these drugs reverse the biochemical, physiological and behavioral deficits in animal models of NS. One of these pharmacological inhibitors (lovastatin), currently being tested in NF1 clinical trials, could also eventually be tested in NS clinical trials.
The animal model studies proposed here are designed to further the understanding of mechanisms of learning and memory, including those involved in the learning disabilities associated with two related genetic disorders: Neurofibromatosis type I (NF1) and Noonan syndrome (NS). Additionally, the drug studies proposed could be the preface for clinical trials of cognitive deficits associated with NS, and other mental health disorders, including learning disabilities, autism and schizophrenia.
|Oh, Jun-Young; Rhee, Sangmyung; Silva, Alcino J et al. (2017) Noonan syndrome-associated SHP2 mutation differentially modulates the expression of postsynaptic receptors according to developmental maturation. Neurosci Lett 649:41-47|
|Rogerson, Thomas; Jayaprakash, Balaji; Cai, Denise J et al. (2016) Molecular and Cellular Mechanisms for Trapping and Activating Emotional Memories. PLoS One 11:e0161655|
|Bearden, Carrie E; Hellemann, Gerhard S; Rosser, Tena et al. (2016) A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. Ann Clin Transl Neurol 3:266-79|
|Cai, Denise J; Aharoni, Daniel; Shuman, Tristan et al. (2016) A shared neural ensemble links distinct contextual memories encoded close in time. Nature 534:115-8|
|Petrella, L I; Cai, Y; Sereno, J V et al. (2016) Brain and behaviour phenotyping of a mouse model of neurofibromatosis type-1: an MRI/DTI study on social cognition. Genes Brain Behav 15:637-46|
|Tomson, Steffie N; Schreiner, Matthew J; Narayan, Manjari et al. (2015) Resting state functional MRI reveals abnormal network connectivity in neurofibromatosis 1. Hum Brain Mapp 36:4566-81|
|Korf, Bruce; Ahmadian, Reza; Allanson, Judith et al. (2015) The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. Am J Med Genet A 167A:1741-6|
|Kastellakis, George; Cai, Denise J; Mednick, Sara C et al. (2015) Synaptic clustering within dendrites: an emerging theory of memory formation. Prog Neurobiol 126:19-35|
|Omrani, A; van der Vaart, T; Mientjes, E et al. (2015) HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry 20:1311-21|
|Silva, Alcino J; Müller, Klaus-Robert (2015) The need for novel informatics tools for integrating and planning research in molecular and cellular cognition. Learn Mem 22:494-8|
Showing the most recent 10 out of 19 publications